BioNTech SE (BNTX) Stock Valuation — PE Analysis

Biotechnology · NASDAQ

Current Price

$80.96

PE Ratio (TTM)

n/m

Intrinsic Value

Use the calculator below to estimate

AI MOAT & RISK ANALYSIS
AI Generated · For Reference OnlyBNTX

COMPETITIVE MOAT

↑mRNA Technology Leadership

BioNTech possesses a leading position in mRNA technology, a platform with broad therapeutic potential beyond vaccines. This expertise creates a significant barrier to entry for competitors seeking to replicate their advanced capabilities.

↑Oncology Pipeline Expansion

The company is aggressively pivoting its mRNA platform towards a deep pipeline of oncology treatments. This strategic diversification aims to reduce reliance on COVID-19 vaccines and capture future growth in a high-demand area.

↑Strategic Partnerships

BioNTech has established key partnerships, such as with Pfizer for COVID-19 vaccines. These collaborations provide access to resources, distribution channels, and validation, strengthening its market position.

INVESTMENT RISKS

↓Regulatory Hurdles and Approval Delays

The development and approval of novel therapeutics, especially in oncology, are subject to stringent regulatory processes. Delays or rejections can significantly impact BioNTech's revenue and growth prospects.

↓Dependence on Future Pipeline Success

While diversifying, BioNTech's future growth is heavily dependent on the successful development and commercialization of its new pipeline candidates. Failure in these ventures poses a substantial risk.

↓Cash Flow and Profitability Concerns

Negative cash flow and concerns about profitability, as noted in recent analyses, indicate potential financial strain. This could limit investment in R&D and expansion, impacting long-term competitiveness.

This company has negative earnings, so a P/E model may not be meaningful — it values profits. You can still use the calculator below with your own assumptions.

Customize the BNTX PE valuation

Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for BioNTech SE respond.

Open PE Calculator for BNTX

Or try DCF Valuation for BNTX →

Company Overview

BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.

Financial Metrics — BNTX PE Stock Valuation Data

PE Ratio (TTM)

n/m

PEG Ratio

0.13

Earnings Yield

-8.16%

ROE (TTM)

-8.1%

Revenue/Share (TTM)

$9.68

Debt/Equity

0.02x

Frequently Asked Questions

What is the PE ratio of BNTX?

The trailing twelve-month PE ratio of BNTX reflects how much investors pay per dollar of BioNTech SE's earnings. This metric is most useful when compared to Biotechnology peers and the company's own historical range.

Is BNTX overvalued based on PE ratio?

BNTX's PE of -12.4x combined with a PEG ratio of 0.13 provides a growth-adjusted perspective. A PEG below 1.0 means the P/E is low relative to the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Biotechnology, a DCF analysis may be more appropriate.

How do I value BNTX stock using PE ratio?

To value BioNTech SE using PE: (1) Compare the current PE (-12.4x) against the Biotechnology median to assess relative pricing, (2) check the PEG ratio (0.13) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.

What is the PEG ratio of BNTX?

BNTX's PEG ratio is 0.13, calculated by dividing the PE ratio (-12.4x) by the expected earnings growth rate. A PEG below 1.0 means the P/E is low relative to the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.

Should I use PE ratio or DCF for BNTX stock valuation?

PE ratio gives a quick relative read — how BNTX is priced versus Biotechnology peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.

Learn More

Related PE Valuations

All Healthcare valuations

P/E and DCF value BNTX with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.

Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.

This is an estimate, not investment advice.